Stock Taper 
Pulmonx Corporation develops minimally invasive devices like Zephyr Valves and assessment systems for treating severe emphysema, providing diagnostic and treatment solutions globally.
The Zephyr Endobronchial Valve is a minimally invasive device that improves breathing and quality of life for severe emphysema patients by blocking diseased lung areas during a bronchoscopic procedure.
On October 27, 2025, Pulmonx announced the reappointment of former President and CEO Glen French, and the appointment of Derrick Sung as the new COO and CFO. This news came as the company also released preliminary third-quarter revenue of approximately $21.5 million, exceeding analyst expectations. The combination of the leadership transition and the positive revenue surprise led to a significant surge in investor confidence and stock price.
Pulmonx Corporation announced the immediate resignation of President and CEO Steve Williamson and another executive, reappointing former President and CEO Glen French to the top role. This move signals a significant change in leadership and strategic direction for the company, coinciding with the announcement of preliminary Q3 2025 revenue.
Pulmonx (NASDAQ: LUNG - Get Free Report) and Owlet (NYSE: OWLT - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability and analyst recommendations. Institutional and Insider Ownership 91.0% of Pulmonx shares are
Overall rating: C+
| PEER | PRICE | |
|---|---|---|
 RLMD | $3.29 | COMPARE |
 VXRT | $0.43 | COMPARE |
 IMUX | $7.65 | COMPARE |
 ACRV | $1.89 | COMPARE |
 PMVP | $1.50 | COMPARE |
 HYPR | $0.87 | COMPARE |
 TELA | $1.05 | COMPARE |
 TCRX | $0.28 | COMPARE |
